Balance Sheet Parenthetical [Abstract]
Balance Sheet Parenthetical [Abstract]
Common stock, par value
Common Stock, Par or Stated Value Per Share
Common stock, shares authorized
Common Stock, Shares Authorized
Common stock, shares issued
Common Stock, Shares, Issued
Common stock, shares outstanding
Common Stock, Shares, Outstanding
Research and Development [Abstract]
Procurement Contract and Research Agreements
Procurement Contract and Research Agreements [Text Block]
The entire disclosure for procurement contracts and research agreements including grants or contracts from various agencies of the U.S. government to support the reporting entity's research and development activities.
Fair Value Measurements [Abstract]
Fair Value Measurements [Abstract]
Fair Value Disclosures
Fair Value Disclosures [Text Block]
Earnings Per Share [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]
Antidilutive Securities [Axis]
Antidilutive Securities [Axis]
Antidilutive Securities, Name [Domain]
Antidilutive Securities, Name [Domain]
Stock Option [Member]
Employee Stock Option [Member]
Stock Appreciation Rights (SARs) [Member]
Stock Appreciation Rights (SARs) [Member]
Restricted Stock Units (RSUs) [Member]
Restricted Stock Units (RSUs) [Member]
Warrants [Member]
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Restricted Stock Units
Restricted Stock Units
Restricted Stock Units have been vested but not converted into common stock
Weighted average
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities [Text Block]
The entire disclosure for accrued liabilities and other current liabilities at the end of the reporting period.
Bonus
Accrued Bonuses, Current
Professional fees
Accrued Professional Fees, Current
Vacation
Accrued Vacation, Current
Taxes Payable
Taxes Payable
Accounts Payable and Accrued Liabilities
Accounts Payable and Accrued Liabilities
Other
Other Accrued Liabilities, Current
Total
Accrued Liabilities, Current
Liabilities Subject to Compromise [Abstract]
Liabilities subject to compromise
Reorganization under Chapter 11 of US Bankruptcy Code Disclosure [Text Block]
Income Tax Disclosure [Abstract]
Income Tax
Income Tax Disclosure [Text Block]
Document and Entity Information [Abstract]
Document and Entity Information [Abstract]
Document Information [Table]
Document Information [Table]
Document Information, Document [Axis]
Document Information, Document [Axis]
Document [Domain]
Document [Domain]
Document Information [Line Items]
Document Information [Line Items]
Entity Registrant Name
Entity Registrant Name
Entity Central Index Key
Entity Central Index Key
Current Fiscal Year End Date
Current Fiscal Year End Date
Entity Filer Category
Entity Filer Category
Trading Symbol
Trading Symbol
Document Type
Document Type
Document Period End Date
Document Period End Date
Document Fiscal Year Focus
Document Fiscal Year Focus
Document Fiscal Period Focus
Document Fiscal Period Focus
Amendment Flag
Amendment Flag
Entity Common Stock, Shares Outstanding
Entity Common Stock, Shares Outstanding
Equity [Abstract]
Class of Warrant or Right [Table]
Class of Warrant or Right [Table]
Scenario [Axis]
Scenario [Axis]
Scenario, Unspecified [Domain]
Scenario, Unspecified [Domain]
Extended Expiration Period [Member]
Extended Expiration Period [Member]
Extended Expiration Period [Member]
Related Party [Axis]
Related Party [Axis]
Related Party [Domain]
Related Party [Domain]
Affiliated Entity [Member]
Affiliated Entity [Member]
Fair Value, Hierarchy [Axis]
Fair Value, Hierarchy [Axis]
Fair Value Hierarchy [Domain]
Fair Value Hierarchy [Domain]
Fair Value, Inputs, Level 2 [Member]
Fair Value, Inputs, Level 2 [Member]
Measurement Frequency [Axis]
Measurement Frequency [Axis]
Fair Value, Measurement Frequency [Domain]
Fair Value, Measurement Frequency [Domain]
Fair Value, Measurements, Recurring [Member]
Fair Value, Measurements, Recurring [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right [Line Items]
Change in fair value of common stock warrants
Change In Fair Value Of Common Stock Warrants
The aggregate adjustment to the fair market value of liability classified warrants to purchase common stock.
Commitment to Invest
Commitment to Invest
Related party commitment to invest at the Company's discretion in exhange for common stock and warrants.
Warrants to purchase percentage of acquired shares
Warrants to Purchase Percentage of Shares
Related party commitment to invest at the Company's discretion in exhange for warrants to purchase a percentage of the number of Company shares acquired by the related party.
Warrants to purchase common stock
Class of Warrant or Right, Number of Securities Called by Warrants or Rights
Proceeds from issuance of warrants and options
Proceeds From Issuance Of Warrants and Options 1
The cash inflow associated with both the amount received from holders exercising their stock options and issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.
Exercise price of warrants to purchase common stock
Class of Warrant or Right, Exercise Price of Warrants or Rights
Service agreement term
Service Agreement Term 1
Service agreement, entered into with MacAndrews & Forbes LLC ("M&F"), in years.
Warrants contractrual term
Warrants contractrual term
The contractual life of warrants.
Expense of warrants held as assets
Expense of Warrants Held as Assets
The expense associated with warrants held as assets.
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment
Property, Plant and Equipment Disclosure [Text Block]
Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities [Table Text Block]
Tabular disclosure of the components of accrued liabilities and other current liabilities.
Income Statement [Abstract]
Statement [Table]
Statement [Table]
Statement [Line Items]
Statement [Line Items]
Revenues
Revenues [Abstract]
Research and development
Research and Development Revenue
Revenue earned during the period arising from services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts and any other contract related to a particular project or product.
Operating expenses
Operating Expenses [Abstract]
Selling, general and administrative
Selling, General and Administrative Expense
Research and development
Research and Development Expense
Patent preparation fees
Patent Preparation Fees
The aggregate costs incurred for fees associated with the protection and expansion of patents and related intellectual property.
PharmAthene liability interest
PharmAthene liability interest
Amount of costs on PharmAthene liability accounted as interest expense
Interest on PharmAthene liability
Interest on PharmAthene liability
Interest on PharmAthene liability
Total operating expenses
Operating Expenses
Operating loss
Operating Income (Loss)
Decrease (increase) in fair value of common stock warrants
Non-cash interest expense
Interest Expense
Other income, net
Nonoperating Income (Expense)
Reorganization items, net
Reorganization Items
Loss before income taxes
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest
Benefit from (provision for) income taxes
Income Tax Expense (Benefit)
Net and comprehensive income (loss)
Net Income (Loss) Attributable to Parent
Earnings (loss) per share: basic and diluted
Earnings Per Share, Basic and Diluted
Weighted average shares outstanding: basic and diluted
Weighted Average Number of Shares Outstanding, Basic and Diluted
Commitments and Contingencies Disclosure [Abstract]
Loss Contingencies [Table]
Loss Contingencies [Table]
Litigation Case [Axis]
Litigation Case [Axis]
Litigation Case Type [Domain]
Litigation Case [Domain]
License Agreement litigation
License Agreement Litigation [Member]
License Agreement Litigation [Member]
Litigation Status [Axis]
Litigation Status [Axis]
Litigation Status [Domain]
Litigation Status [Domain]
Pending litigation
Pending Litigation [Member]
Loss Contingency Nature [Axis]
Loss Contingency Nature [Axis]
Loss Contingency, Nature [Domain]
Loss Contingency, Nature [Domain]
Surety bond
Surety Bond [Member]
Balance Sheet Location [Axis]
Balance Sheet Location [Axis]
Balance Sheet Location [Domain]
Balance Sheet Location [Domain]
Accrued liabilities
Accrued Liabilities [Member]
Other assets
Other Assets [Member]
Loss Contingencies [Line Items]
Loss Contingencies [Line Items]
Percentage of net profits from sales after net profit threshold
Percentage of Net Profits from Sales After Net Profit Milestone Resulting From Award Damages
The Delaware Court of Chancery awarded to PharmAthene an equitable payment stream or equitable lien consisting of fify percent of the net profits that the Company achieves from sales of ST-246 after the Company secures $40 million in net profits, for ten years following the first commercial sale.
Net profit threshold
Net Profit Milestone
The Delaware Court of Chancery awarded to PharmAthene an equitable payment stream or equitable lien consisting of fify percent of the net profits that the Company achieves from sales of ST-246 after the Company secures $40 million in net profits, for ten years following the first commercial sale
Equitable payment stream following first commercial sale, duration
Duration of Equitable Payment Stream Following First Commercial Sale
The Delaware Court of Chancery awarded to PharmAthene an equitable payment stream or equitable lien consisting of fify percent of the net profits that the Company achieves from sales of ST-246 after the Company secures $40 million in net profits, for ten years following the first commercial sale.
Percentage of litigation costs awarded
Litigation Costs Awarded, Percentage
The Delaware Court of Chancery awarded PharmAthene one-third of its reasonable attorneys' fees and expert witness expenses.
Plaintiff attorneys' fee and expenses
Amount Plaintiff May Recover
The Delaware Court of Chancery awarded PharmAthene one-third of its reasonable attorneys' fees and expert witness expenses.
Payment to Post Collateral for Surety Bond
Payment to Post Collateral for Surety Bond
Payment to post collateral for surety bond.
Collateral
Collateral
Percentage of cash collateral for surety bond.
Surety bond
Surety bond
Amount of surety bond.
Litigation costs awarded, remand proceedings
Litigation Costs Awarded, Remand Proceedings
The Delaware Court of Chancery awarded PharmAthene one-third of its reasonable attorneys' fees and expenses it incurred in the remand proceedings.
Litigation costs awarded, pretrial and trial phases
Litigation Costs Awarded, Pretrial and Trial Phases
The Delaware Court of Chancery awarded PharmAthene a percentage of its expert witness fees it incurred in the pretrial and trial phases.
Litigation costs awarded, expert fees remand proceedings
Litigation Costs Awarded, Expert Fees Remand Proceedings
The Delaware Court of Chancery awarded PharmAthene a percentage of its expert witness fees it incurred in remand proceedings.
Final Order And Judgment
Final Order And Judgment
Final order and judgment entered by the Court awarding damages to the Plaintiff.
Final order and judgment including interest
Final order and judgment plus interest
Final Order and Judgment entered by the Court awarding expectation damages, plus pre-judgment interest, and certain permitted legal fees, costs, and expenses to Plaintiff.
Final order and judgment post-judgment interest
Final Order And Judgment Post-Judgment Interest
Final order and judgment post-judgment interest entered by the Court awarding damages to the Plaintiff.
Per Diem Interest
Per Diem Interest
Per Diem Interest on post judgment amount on the Final Order Judgment entered by the court awarding damages on the PharmAthene litigation
Loss Contingency Accrual
Loss Contingency Accrual
Final Order And Judgment Pre and Post-Judgment Interest
Final Order And Judgment Pre and Post-Judgment Interest
Final Order and Judgment entered by the Court awarding expectation damages, plus pre and post-judgment interest, and certain permitted legal fees, costs, and expenses to Plaintiff.
Liabilities subject to compromise, loss contingency legal fees
Liabilities subject to compromise, loss contingency legal fees
The amount of pre-petition loss contingency liability representing legal and expert fees accrued and included in liabilities subject to compromise.
Loss Contingency, Accrual, Current
Loss Contingency, Accrual, Current
PharmAthene liability includes reimbursable attorney and expert fee
PharmAthene liability includes reimbursable attorney and expert fee
PharmAthene liability includes reimbursable attorney and expert fee
Inventory [Abstract]
Inventory [Abstract]
Inventory
Schedule of Inventory, Current [Table Text Block]
Current income tax expense (benefit)
Current Income Tax Expense (Benefit)
Income (loss) from continuing operations before income taxes
Income (Loss) from Continuing Operations before Income Taxes, Domestic
Write-off of leasehold improvements
Gain (Loss) on Disposition of Property Plant Equipment
Leasehold improvements, gross
Leasehold Improvements, Gross
Computer equipment, gross
Computer Equipment
The gross amount of capitalized computer equipment costs as of the balance sheet date.
Furniture and fixtures, gross
Furniture and Fixtures, Gross
Property, plant and equipment, gross
Property, Plant and Equipment, Gross
Accumulated depreciation, depletion and amortization, property, plant, and equipment
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
Property, plant and equipment, net
Property, Plant and Equipment, Net
Depreciation and other amortization
Depreciation, Depletion and Amortization
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]
Stockholders' Equity Note Disclosure [Text Block]
Financial Instruments Disclosure [Text Block]
Inventory Disclosure [Abstract]
Inventory, Current [Table]
Inventory, Current [Table]
Procurement Contract [Axis]
Procurement Contract [Axis]
Procurement Contract [Axis]
Procurement Contract [Domain]
Procurement Contract [Domain]
Procurement Contract [Domain]
BARDA Contract
Barda Contract [Member]
Barda Contract [Member]
Inventory [Line Items]
Inventory [Line Items]
Courses delivered provisional dosage, twice daily
Courses Delivered Provisional Dosage, Twice Daily
Courses of tecovirimat delivered to the Strategic Stockpile at the provisional dosage of 600 mg twice daily (1,200 mg per day).
Work in process
Inventory, Work in Process and Raw Materials
Finished goods
Inventory, Finished Goods, Net of Reserves
Inventory
Inventory, Net
Inventory write-downs
Inventory Write-downs
Inventory write-downs included in research and development expense on the balance sheet.
Bankruptcy Claims, Amount Paid to Settle Claims
Bankruptcy Claims, Amount Paid to Settle Claims
Bankruptcy Claims, Number Of Claims Outstanding
Bankruptcy Claims, Number Of Claims Outstanding
The aggregate number of claims outstanding with the bankruptcy court.
Liabilities subject to compromise, other accrued expense
Liabilities subject to compromise, other accrued expense
The amount of pre-petition accrued expense included in liabilities subject to compromise.
Liabilities subject to compromise, accounts payable
Liabilities subject to compromise, accounts payable
The amount of pre-petition trade accounts payable included in liabilities subject to compromise.
Amount To Be Paid On Effective Date of Plan Of Reorganization
Amount To Be Paid On Effective Date of Plan Of Reorganization
The amount the Company is to pay PharmAthene on the effective date of the plan of reorganization.
payment to extend 120 days to satisfy pharmAthene claim
payment to extend 120 days to satisfy pharmAthene claim
payment to extend 120 days to satisfy pharmAthene claim
Payment To Extend Days To Satisfy Claim
Payment To Extend Days To Satisfy Claim
Total amount of payment to PharmAthene to extend the number of days to satisfy the claim.
Covenants on pharmAthene liability
Covenants on pharmAthene liability
Covenants on pharmAthene liability is amounts to be paid to PharmAthene in excess of $50 million in the event of default with respect to a covenant.
Liabilities Subject to Compromise
Liabilities Subject to Compromise
Net Capital Deficiency
Net Capital Deficiency
Net Capital Deficiency. Net capital is equal to the net worth of the broker dealer, less certain items such as exchange memberships, carrying value of securities not readily marketable, haircuts on marketable securities in proprietary accounts, furniture and equipment and other illiquid assets as defined.
Per Share Data
Earnings Per Share [Text Block]
Commitments and Contingencies
Commitments and Contingencies Disclosure [Text Block]
Recent Accounting Pronouncements [Abstract]
Recent Accounting Pronouncements [Abstract]
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]
Statement of Financial Position [Abstract]
ASSETS
Assets [Abstract]
Cash and cash equivalents
Cash and Cash Equivalents, at Carrying Value
Restricted cash
Restricted Cash and Investments, Current
Accounts receivable
Accounts Receivable, Net, Current
Prepaid expense and other assets, current
Prepaid Expense and Other Assets, Current
Deferred tax assets
Deferred Tax Assets, Net of Valuation Allowance, Current
Total current assets
Assets, Current
Property, plant and equipment, net
Deferred costs
Deferred Costs, Noncurrent
Goodwill
Goodwill
Other assets
Other Assets, Noncurrent
Total assets
Assets
LIABILITIES AND STOCKHOLDERS' EQUITY
Liabilities and Equity [Abstract]
Accounts payable
Accounts Payable, Current
Accrued expenses and other current liabilities
Long-term debt, current maturities
Long-term Debt, Current Maturities
Total current liabilities
Liabilities, Current
Deferred revenue
Deferred Revenue, Noncurrent
Deferred income tax liability
Deferred Tax Liabilities, Net, Noncurrent
Other liabilities
Other Liabilities
Liabilities subject to compromise
Total liabilities
Liabilities
Stockholders' equity
Stockholders' Equity Attributable to Parent [Abstract]
Common stock ($.0001 par value, 100,000,000 shares authorized, 53,843,044 and 53,504,296 issued and outstanding at June 30, 2015, and December 31, 2014, respectively
Common Stock, Value, Issued
Additional paid-in capital
Additional Paid in Capital, Common Stock
Accumulated deficit
Retained Earnings (Accumulated Deficit)
Total stockholders' equity
Stockholders' Equity Attributable to Parent
Total liabilities and stockholders' equity
Liabilities and Equity
Related Party Transactions [Abstract]
Related Party Transactions
Related Party Transactions Disclosure [Text Block]
Procurement Contract [Table]
Procurement Contract [Table]
Procurement Contract [Table]
Range [Axis]
Range [Axis]
Range [Domain]
Range [Domain]
Minimum [Member]
Minimum [Member]
Maximum [Member]
Maximum [Member]
Procurement Contract [Line Items]
Procurement Contract [Line Items]
Procurement Contract [Line Items]
Number of courses to be delivered
Number of Courses To Be Delivered 1
Number of tecovirimat, also known as ST-246, courses to be delivered to the U.S. Strategic National Stockpile
Value of contract
Government Contract, Value of Award 1
Value of base contract award.
Contract Value of Manufacturing and Delivery Activities
Contract Value of Manufacturing and Delivery Activities
Contract value of manufacturing and delivery activities.
Contract value of development and support activities
Contract Value of Development and Support Activities
Contract value of development and support activities
Contract value of various options
Contract Value of Various Options
Contract value of various options exercisable at BARDA's discretion.
Amount of option to be received from BARDA for approval for extension of 84 moth expiry
Amount of option to be received from BARDA for approval for extension of 84 moth expiry
Amount of option to be received from BARDA for approval for extension of 84 moth expiry
Contract Value, Option, FDA Approval
Contract Value, Option, FDA Approval
Contract value of option exercisable, FDA approval for extension to 84-month expiry for Tecovirimat, at BARDA's discretion.
Contract Value, Detail Of Option Exercisable, Development Activities
Contract Value, Detail Of Option Exercisable, Development Activities
Contract value of option exercisable, amount represents exercisable option that would fund development and support activities, at BARDA's discretion.
Contract Value, Detail Of Option Exercisable, Production Activities
Contract Value, Detail Of Option Exercisable, Production Activities
Contract value of option exercisable, amount represents exercisable option that would fund production activities, at BARDA's discretion.
Number of courses under modified contract
Government Contract, Number of Courses Purchased Under Modified Contract
Government contract, number of courses to be purchased under modified contract.
Increase in payments for delivery of courses of TPOXX
Increase in payments for delivery of courses of TPOXX
Increase in payments for delivery of courses of TPOXX
Holdback amount pending FDA approval
Holdback amount pending FDA approval
Holdback amount pending FDA approval
Reduced holdback amount
Reduced holdback amount
Reduced holdback be received from BARDA
Number of courses contributed at no additional cost to the government
Government Contract, Number of Free Courses
Number of courses of tecovirimat to be contributed to the Strategic Stockpile at no cost to the government.
Proceeds from manufacture and physical delivery of courses, government contract
Proceeds From Manufacture And Physical Delivery Of Courses, Government Contracts
Proceeds from manufacture and physical delivery of courses, government contracts.
Number of courses delivered to the government
Number of courses delivered to the government
Number of courses delivered to the government
Invoiced milestone
Invoiced milestone
Invoiced milestone
Number of courses of TPOXX to be delivered to the government
Number of courses of TPOXX to be delivered to the government
Number of courses of TPOXX to be delivered to the government
Number of free courses to be delivered to BARDA
Number of free courses to be delivered to BARDA
Number of free courses to be delivered to BARDA
Number of courses to be delivered to the government, including free courses
Number of courses to be delivered to the government, including free courses
Number of courses to be delivered to the government, including free courses
Proceeds from advance payments under the BARDA contract
Proceeds from Advance Payments, Government Contracts
Proceeds from advance payments, government contracts
Milestone payment
Milestone payment
Proceeds from milestone payment, Government contracts
Proceeds From Physical Delivery Of Courses, Government Contracts
Proceeds From Physical Delivery Of Courses, Government Contracts
Proceeds from physical delivery of courses, government contract.
Future proceeds to be received from BARDA
Future proceeds to be received from BARDA
Future proceeds to be received from BARDA
Future proceeds to be received from the future deliveries of courses to the government
Future proceeds to be received from the future deliveries of courses to the government
Future proceeds to be received from the future deliveries of courses to the government
Courses delivered
Number of courses delivered and accepted
Number of tecovirimat, also known as ST-246, courses delivered and accepted to the U.S. Strategic National Stockpile.
Number of courses delivered and accepted at provisional dosage, once daily
Number Of Courses Delivered And Accepted At Provisional Dosage, Once Daily
Number of tecovirimat, also known as ST-246, courses delivered and accepted at the provisional dosage of 600 mg once daily to the U.S. Strategic National Stockpile.
Deferred revenue
Deferred Revenue, Description
Research and development revenue long-term contract
Research and Development Revenue Long-term Contract
Revenue earned during the period arising from research and development services provided under the terms of a long-term contract. May include government contracts and any other contract related to a particular project or product.
Number of active contracts
Number of Active Contracts
Number of active contracts.
Number of active grants
Number of Active Grants
Number of active grants
Potential future research and development funding
Potential Future Aggregate Research and Development Expenses
Potential future aggregate research and development funding for specific projects which includes options that may or may not be exercised at the U.S. government's discretion.
Potential milestone payments
Potential milestone payments
Potential later stage milestone payments and royalties.
Potential royalties
Potential royalties
Maximum percentage of potential royalties on sales of drugs that use transferred intellectual property rights.
Potential percentage cash distributions
Potential percentage cash distributions
Potential percentage cash distributions of profit interest units.
Statement of Cash Flows [Abstract]
Cash and Cash Equivalents, Period Increase (Decrease) [Abstract]
Cash and Cash Equivalents, Period Increase (Decrease) [Abstract]
Cash flows from operating activities:
Net Cash Provided by (Used in) Operating Activities [Abstract]
Net income (loss)
Adjustments to reconcile net income (loss) to net cash used in operating activities
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Depreciation and other amortization
Increase (decrease) in fair value of warrants
Increase In Fair Value Of Warrants
Noncash expense, not otherwise specified in the taxonomy, charged against earnings in the period to adjust the fair market value of liability classified warrants to purchase common stock.
Stock-based compensation
Share-based Compensation
Gain on sale of assets
Gain (Loss) on Disposition of Assets
Non-cash interest expense
Other Noncash Expense
Changes in assets and liabilities:
Increase (Decrease) in Operating Capital [Abstract]
Accounts receivable
Increase (Decrease) in Accounts Receivable
Inventory
Increase (Decrease) in Inventories
Deferred costs
Increase (Decrease) in Deferred Charges
Prepaid expenses and other current assets
Increase (Decrease) in Prepaid Expense
Other assets
Increase (Decrease) in Other Operating Assets
Deferred income taxes, net
Deferred Income Tax Expense (Benefit)
Accounts payable, accrued expenses and other current liabilities
Increase (Decrease) in Accounts Payable and Accrued Liabilities
Increase/decrease in PharmAthene liability
Increase/decrease in PharmAthene liability
Increase/decrease in PharmAthene liability value is as of balance sheet date of liability incurred and payable to PharmAthene for litigation against the Company which damages awarded to PharmAthene by the court.
PharmAthene liability
PharmAthene liability
PharmAthene liability is carrying value as of balance sheet date of liability and payable to PharmAthene for litigation against the Company for which damages awarded to PharmAthene by the court.
Liabilities subject to compromise
Liabilities Subject to Compromise, Period Increase (Decrease)
Deferred revenue
Increase (Decrease) in Deferred Revenue
Other liabilities
Increase (Decrease) in Other Operating Liabilities
Net cash provided by (used in) operating activities
Net Cash Provided by (Used in) Operating Activities
Cash flows from investing activities:
Net Cash Provided by (Used in) Investing Activities [Abstract]
Capital expenditures
Payments to Acquire Property, Plant, and Equipment
Proceeds from sale of assets
Proceeds from Sale of Productive Assets
Restricted Cash
Payments for (Proceeds from) Other Investing Activities
Net cash (used in) provided by investing activities
Net Cash Provided by (Used in) Investing Activities
Cash flows from financing activities:
Net Cash Provided by (Used in) Financing Activities [Abstract]
Net proceeds from exercise of warrants and options
Proceeds From Issuance Of Warrants and Options
The cash inflow associated with both the amount received from holders exercising their stock options and issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.
Payment of common stock tendered for employee tax obligations
Payments Related to Tax Withholding for Share-based Compensation
Repayments of long-term debt
Repayments of Long-term Debt
Net cash provided by financing activities
Net Cash Provided by (Used in) Financing Activities
Net increase (decrease) in cash and cash equivalents
Cash and Cash Equivalents, Period Increase (Decrease)
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Schedule of Related Party Transactions, by Related Party [Table]
Schedule of Related Party Transactions, by Related Party [Table]
Member of Board of Directors
Management [Member]
Related Party Transaction [Line Items]
Related Party Transaction [Line Items]
Free rent period
Free Rent Period
Free Rent Period in months allowed under the sublease.
Monthly rental payments first five years
Monthly Rental Payments First Five Years
The amount of the monthly rental payments due under the sublease entered into for the first five years.
Initial rent period
Initial Rent Period
Represents the number of years for the initial rent period of five years and related monthly payments.
Monthly rental payments after five years
Monthly Rental Payments After Five Years
The amount of the monthly rental payments due under the sublease entered into after the first five years.
Rent period after first five years
Rent Period After First Five Years
Represents the amount of years after the initial rent period of first five years of which monthly rental payments will increase.
Legal fees
Legal Fees
Accounts payable to related party
Accounts Payable, Related Parties
Related party expense
Related Party Transaction, Expenses from Transactions with Related Party
Fair Value Measurements, Recurring and Nonrecurring [Table]
Fair Value Measurements, Recurring and Nonrecurring [Table]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Term loan
Debt, Long-term and Short-term, Combined Amount
Inventory
Inventory Disclosure [Text Block]
Liabilies subject to compromise [Table Text Block]
Liabilies subject to compromise [Table Text Block]
[Table Text Block] for Schedule of liabilities that are subject to compromise.
Reorganization items [Table Text Block]
Reorganization items [Table Text Block]
The schedule represents a summary of reorganization items.
Schedule of antidilutive securities excluded from computation of earnings per share
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Property, plant and equipment
Property, Plant and Equipment [Table Text Block]
Reorganization [Abstract]
Reorganization [Abstract]
Debtor reorganization items, Legal fees
Debtor Reorganization Items, Legal and Advisory Professional Fees
Reorganization, Professional fees
Reorganization, Professional Fees
Amount of reorganization items related to professional fees related to entities in bankruptcy.
Reorganization, Trustee fees
Reorganization, Trustee fees
Amount of reorganization items for trustee fees related to entities in bankruptcy.
Debtor Reorganization Items, Other expense
Debtor Reorganization Items, Other Expense (Income)
Reorganization Items
Reorganization payments
Reorganization Payments
The amount the Company paid for reorganization items.